Effectiveness of adaptive designs for phase II cancer trials

Contemporary Clinical Trials

Volumn 33, Issue 1, 2012, Pages 223-227

  López, Martha Fors ^a   Dupuy, Jean François ^b   Gonzalez, Carmen Viada ^c  

^a National Coordinating Centre for Clinical Trials   (Cuba)

^b UNIVERSITÉ DE LA ROCHELLE   (France)

^c CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Adaptive designs; Cancer trials; Phase II trials; Traditional designs

Indexed keywords

ADAPTIVE DESIGN; ARTICLE; BAYES THEOREM; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RESEARCH; COLON CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; METHODOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PUBLICATION; SAMPLE SIZE; TRADITIONAL DESIGN;

CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84855350870     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.09.017     Document Type: Article

References (14)

1. Innovation or Stagnation: Challenges and Opportunity on the Critical Path to New Medical Products Food and Drug Administration. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
2. Adjei A., Christian M., Ivy P. Novel designs and end points for phase II clinical trials. Clin Cancer Res 2009, 15(6):1866-1872.
3. Parmar M.K.B., Barthel F.M.S., Sydes M., Langley R., Kaplan R., Eisenhauer E., et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst September 3 2008, 100(17):1204-1214.
4. Wieand H.S. Randomized phase II trials: what does randomization gain?. J Clin Oncol 2005, 23:1794-1795.
5. Guidance for Industry Adaptive Design Clinical Trials for Drugs and Biologics http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf.
6. Rosenberger W.F. New directions in adaptive designs. Stat Sci 1996, 11(2):137-149.
7. Scott C.T., Baker M. Overhauling clinical trials. Nat Biotechnol 2007, 25:287-292.
8. Weijer C., Shapiro S.H., Glass K.C., Enkin M.W. Clinical equipoise and not the uncertainty principle is the moral underpinning of the randomised controlled trial. Br J Med 2000, 321:756-758.
9. Chow S.-C., Chow S.-C., Chang M. Adaptive designs methods in clinical trials 2007, Chapman and Hall/CRC, Boca Raton.
10. Rogatko A., Babb J.S., Tighiouart M., Khuri F.R., Hudes G. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res 2005, 11(15):5342-5346.
11. Rogatko A., Schoeneck D., Jonas W., Tighiouart M., Khuri F.R., Porter A. Translation of innovative designs into phase I trials. J Clin Oncol Nov 1 2007, 25(31):4982-4986.
12. Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D. Health Care Report. Business Insight; 2008.
13. Chaomei C., Yunan C. Searching for clinical evidence in citespace. AMIA Annu Symp Proc 2005, 2005:121-125.
14. George S. Statistical issues in translational cancer research. Clin Cancer Res 2008, 14(19):5954-5958.